Clinical trials: Low Grade Glioma
Brain Tumor, Low Grade Glioma
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects.
- Conditions
- Brain Tumor, Low Grade Glioma, Astrocytoma, Ependymoma
- Trial name
- NCT01288235
- Testing
- Proton radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Brain and Central Nervous System Tumors
Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00891722
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352495
- Testing
- carboplatin, vinblastine sulfate
- Where
- 21 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Low Grade Glioma of Brain
Surgical Management of Low Grade Glioma
To assess the morbidity and mortality in low grade glioma patients following surgical management.
- Trial name
- NCT06499922
- Testing
- SURGICAL EXCISION
- Volunteers
- 100 people
- Sponsor
- Assiut University
Brain Cancer, Brain Tumor
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
The purpose of this study is to assess the ability of the home-based intervention, HOBSCOTCH-CA, to improve the quality of life and cognitive function in Service Members, Veterans and civilians who are survivors of brain cancer…
- Conditions
- Brain Cancer, Brain Tumor, Brain Neoplasms, Primary Brain Tumor
- Trial name
- HOBSCOTCH-CA (NCT06930846)
- Testing
- HOBSCOTCH-CA
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Low Grade Glioma
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less…
- Trial name
- NCT02840409
- Testing
- Vinblastine, Bevacizumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 109 people
- Sponsor
- The Hospital for Sick Children
Oligodendroglioma, Low-grade Oligodendroglioma
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration.
- Conditions
- Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion
- Trial name
- POLO (NCT04702581)
- Testing
- PCV chemotherapy, Radiotherapy and PCV chemotherapy
- Where
- 26 sites in France
- Volunteers
- 280 people
- Sponsor
- Hospices Civils de Lyon
Low Grade Glioma
ROCOCO - Low Grade Glioma - Planning Study
The cost of particle therapy (PT) are considerably higher than conventional radiotherapy (RT) with photons. Considering potential dosimetric advantages of PT, it is necessary to determine if PT are more cost-effective than…
- Trial name
- ROCOCO LGG (NCT02607397)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht Radiation Oncology
Brain and Central Nervous System Tumors
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as cisplatin and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00360945
- Testing
- cisplatin, temozolomide, fluorescence in situ hybridization
- Where
- 23 sites in France, Ireland and 1 more
- Volunteers
- 87 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Neuroblastoma
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005955
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Duke University
Glioblastoma, IDH1 Gene Mutation
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back.
- Conditions
- Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma
- Trial name
- PNOC017 (NCT03749187)
- Testing
- PARP Inhibitor BGB-290, Temozolomide (TMZ)
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002463
- Testing
- MOPP Regimen, Leucovorin Calcium, Mechlorethamine Hydrochloride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
IDH Wildtype Glioblastoma, IDH Mutant Lower-Grade Gliomas
Metabolomics and Transcriptomics of Low- and High-Grade Gliomas
The goal of this observational study is to better define the molecular profile of rare brain tumors (gliomas) based on the levels of their metabolites and transcripts (the intermediate step between DNA information and proteins).
- Trial name
- GlioMeTra (NCT07832734)
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Low Grade Glioma, Glioblastoma
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-[18F]fluoroethyl)-l-tryptophan ([18F]FETrp) in patients diagnosed with a glioma.
- Trial name
- NCT07735819
- Testing
- Minocycline 200mg/day, [18F]FETrp PET/CT
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain and Central Nervous System Tumors
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent…
- Trial name
- NCT00003467
- Testing
- carmustine, polifeprosan 20 with carmustine implant, surgical procedure
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Duke University
Low-grade Gliomas
Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who have failed initial conventional treatment.
- Trial name
- NCT00901849
- Testing
- Tarceva and Rapamycin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roger Packer
Glioma, Glioblastoma
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2).
- Conditions
- Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma
- Trial name
- NCT03718767
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002944
- Testing
- carboplatin, lomustine, procarbazine hydrochloride
- Where
- 204 sites in United States, Australia and 4 more
- Volunteers
- 428 people
- Sponsor
- Children's Oncology Group
Anaplastic Ependymoma, Ependymoma
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Background: Ependymomas are rare tumors that arise from the ependyma. That is a tissue of the central nervous system. They can develop in the brain or the spine.
- Conditions
- Anaplastic Ependymoma, Ependymoma, Ependymomas
- Trial name
- NCT03727841
- Testing
- Marizomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor Adult
Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI
Intraoperative ultrasound is a versatile, low-cost imaging tool that has been shown to improve safety and efficacy in brain tumor surgery.
- Trial name
- BrainUS-AI (NCT07376304)
- Testing
- BrainUS-AI real-time intraoperative ultrasound segmentation system
- Volunteers
- 100 people
- Sponsor
- Hospital del Rio Hortega